FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / ScientificWorldJournal / Clinical trials of immunogene therapy for spontaneous tumors...
TheScientificWorldJournal2014; 2014; 718520; doi: 10.1155/2014/718520

Clinical trials of immunogene therapy for spontaneous tumors in companion animals.

Abstract: Despite the important progress obtained in the treatment of some pets' malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system's appropriate modulation may provide effective therapeutic options. In this review we summarize the outcomes of published immunogene therapy veterinary clinical trials reported by many research centers. A variety of tumors such as canine melanoma, soft tissue sarcomas, osteosarcoma and lymphoma, feline fibrosarcoma, and equine melanoma were subjected to different treatment approaches. Both viral and mainly nonviral vectors were used to deliver gene products as cytokines, xenogeneic tumor associated antigens, specific ligands, and proapoptotic regulatory factors. In some cases autologous, allogenic, or xenogeneic transgenic cytokine producing cells were assayed. In general terms, minor or no adverse collateral effects appeared during this kind of therapies and treated patients usually displayed a better course of the disease (longer survival, delayed or suppressed recurrence or metastatic spread, and improvement of the quality of life). This suggests the utility of these methodologies as standard adjuvant treatments. The encouraging outcomes obtained in companion animals support their ready application in veterinary clinical oncology and serve as preclinical proof of concept and safety assay for future human gene therapy trials.
Get Full Text
Publication Date: 2014-11-17 PubMed ID: 25506617PubMed Central: PMC4251357DOI: 10.1155/2014/718520Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article presents a summary of results from various clinical trials that applied immunogene therapy for the treatment of spontaneous tumors in pets. It highlights the effectiveness and safety of this therapy in treating specific types of tumors, indicating that it could be a promising adjuvant treatment.

Summary of Immunogene Therapy Trials

  • The research encompasses a broad array of immunogene therapy trials conducted on a variety of tumors affecting dogs, cats, and horses. These include but are not limited to canine melanoma, soft tissue sarcomas, osteosarcoma, and lymphoma, feline fibrosarcoma, and equine melanoma.
  • The results summarized in this review were reported by numerous research centers, indicating a wide acceptance and implementation of the concept.

Methods Used in the Clinical Trials

  • The trials utilized both viral and nonviral vectors to deliver a variety of gene products – such as cytokines, xenogeneic tumor-associated antigens, specific ligands, and proapoptotic regulatory factors – needed for the treatment.
  • In some instances, the methods included the application of autologous, allogenic, or xenogeneic transgenic cytokine-producing cells.

Outcome of the Trials

  • The research paper highlights that immunogene therapy demonstrated minor or no adverse collateral effects in animals, making it a safe treatment option.
  • Additionally, treated pets generally had a better course of the disease, featuring increased survival, delayed or suppressed recurrence or metastatic spread, and an improved quality of life.
  • This strongly suggests the potential benefit of this therapy as a standard adjuvant treatment, which can supplement the primary treatment method.

Implication for Future Research

  • The promising results achieved in animal trials provide a solid foundation for the potential application of this treatment in veterinary clinical oncology.
  • Beyond that, these results also serve as a preclinical proof of concept and safety assay, providing a green light for initiating human gene therapy trials in the future.

Cite This Article

APA
Glikin GC, Finocchiaro LM. (2014). Clinical trials of immunogene therapy for spontaneous tumors in companion animals. ScientificWorldJournal, 2014, 718520. https://doi.org/10.1155/2014/718520

Publication

TheScientificWorldJournal
ISSN: 1537-744X
NlmUniqueID: 101131163
Country: United States
Language: English
Volume: 2014
Pages: 718520

Researcher Affiliations

Glikin, Gerardo Claudio
  • Unidad de Transferencia Genética, Instituto de Oncología "Ángel H. Roffo", Universidad de Buenos Aires, 1417 Buenos Aires, Argentina.
Finocchiaro, Liliana María Elena
  • Unidad de Transferencia Genética, Instituto de Oncología "Ángel H. Roffo", Universidad de Buenos Aires, 1417 Buenos Aires, Argentina.

MeSH Terms

  • Animals
  • Clinical Trials as Topic
  • Genetic Therapy
  • Immunotherapy
  • Neoplasms / therapy
  • Neoplasms / veterinary
  • Pets / immunology

References

This article includes 66 references
  1. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.. The New England Journal of Medicine 1990;323(9):570–578.
    doi: 10.1056/NEJM199008303230904pubmed: 2381442google scholar: lookup
  2. Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P, Roth C, Mehtali M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.. Gene Therapy 1996;3(12):1104–1112.
    pubmed: 8986437
  3. Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.. Cancer Research 1994;54(22):5757–5760.
    pubmed: 7525049
  4. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer.. Cancer Investigation 2000;18(8):781–792.
    doi: 10.3109/07357900009012210pubmed: 11107448google scholar: lookup
  5. Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use in preclinical cancer drug development.. European Journal of Cancer 2004;40(6):858–880.
    doi: 10.1016/j.ejca.2003.11.031pubmed: 15120042google scholar: lookup
  6. Glikin GC, Finocchiaro LME. Gene therapy for canine cancer: clinical results.. 2012. pp. 37–56.
  7. Finocchiaro LME, Glikin GC. Cancer gene therapy in large animals.. 2008. pp. 279–292.
  8. Liu L, Wang S, Shan B, Sang M, Liu S, Wang G. Advances in viral-vector systemic cytokine gene therapy against cancer.. Vaccine 2010;28(23):3883–3887.
    doi: 10.1016/j.vaccine.2010.03.041pubmed: 20371389google scholar: lookup
  9. Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.. Cancer Gene Therapy 2013;20(2):70–76.
    doi: 10.1038/cgt.2012.95pubmed: 23306610google scholar: lookup
  10. Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods.. Current Pharmaceutical Biotechnology 2013;14(1):46–60.
    doi: 10.2174/138920113804805278pubmed: 23437936google scholar: lookup
  11. Pavlin D, Cemazar M, Sersa G, Tozon N. IL-12 based gene therapy in veterinary medicine.. Journal of Translational Medicine 2012;10(1, article 234).
    doi: 10.1186/1479-5876-10-234pmc: PMC3543347pubmed: 23171444google scholar: lookup
  12. Ohlfest JR, Freese AB, Largaespada DA. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies.. Current Gene Therapy 2005;5(6):629–641.
    doi: 10.2174/156652305774964749pubmed: 16457652google scholar: lookup
  13. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer.. Human Gene Therapy 1998;9(13):1851–1861.
    doi: 10.1089/hum.1998.9.13-1851pubmed: 9741424google scholar: lookup
  14. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.. Journal of Clinical Investigation 1998;101(11):2406–2414.
    doi: 10.1172/JCI510pmc: PMC508830pubmed: 9616212google scholar: lookup
  15. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, Dow SW, Bellgrau D, Cutter GR, Helfand SC, Modiano JF. Enhancing antimelanoma immune responses through apoptosis.. Cancer Gene Therapy 2003;10(9):726–736.
    doi: 10.1038/sj.cgt.7700625pubmed: 12944992google scholar: lookup
  16. Bergman PJ, McKnight J, Novosad A. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.. Clinical Cancer Research 2003;9(4):1284–1290.
    pubmed: 12684396
  17. Liao JCF, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.. Cancer Immunity 2006;6(article 8).
    pmc: PMC1976276pubmed: 16626110
  18. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.. American Journal of Veterinary Research 2011;72(12):1631–1638.
    doi: 10.2460/ajvr.72.12.1631pubmed: 22126691google scholar: lookup
  19. MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, Rodriguez CO Jr, Phillips B, Zwahlen CH, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, Henry C, Fidel J. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.. Clinical Cancer Research 1999;5(12):4249–4258.
    pubmed: 10632367
  20. Bergman PJ, Camps-Palau MA, McKnight JA. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.. Vaccine 2006;24(21):4582–4585.
    doi: 10.1016/j.vaccine.2005.08.027pubmed: 16188351google scholar: lookup
  21. Manley CA, Leibman NF, Wolchok JD. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.. Journal of Veterinary Internal Medicine 2011;25(1):94–99.
    doi: 10.1111/j.1939-1676.2010.0627.xpubmed: 21143299google scholar: lookup
  22. Ottnod JM, Smedley RC, Walshaw R, Hauptman JG, Kiupel M, Obradovich JE. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.. Veterinary and Comparative Oncology 2013;11(3):219–229.
    doi: 10.1111/vco.12057pubmed: 23909996google scholar: lookup
  23. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, Foley R, Kruth S, Liaw PC, Gauldie J. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.. Journal of Veterinary Internal Medicine 2005;19:56–63.
    pubmed: 15715049
  24. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, MacEwen EG, Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.. Cancer Immunology, Immunotherapy 2006;55(4):433–442.
    doi: 10.1007/s00262-005-0025-6pmc: PMC11031070pubmed: 15965647google scholar: lookup
  25. Von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Tötterman TH. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.. Journal of Immunotherapy 2008;31(4):377–384.
    doi: 10.1097/CJI.0b013e31816a812dpubmed: 18391758google scholar: lookup
  26. Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog ASI, Tötterman TH, Von Euler H. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma.. Journal of Immunotherapy 2013;36(6):350–358.
    doi: 10.1097/CJI.0b013e31829d8a1bpubmed: 23799414google scholar: lookup
  27. Riccardo F, Iussich S, Maniscalco L, Lorda-Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.. Clinical Cancer Research 2014;20:3753–3762.
    doi: 10.1158/1078-0432.CCR-13-3042pmc: PMC8656093pubmed: 24874834google scholar: lookup
  28. Finocchiaro LME, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma.. Cancer Gene Therapy 2008;15(3):165–172.
    doi: 10.1038/sj.cgt.7701096pubmed: 18219342google scholar: lookup
  29. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.. Gene Therapy 2008;15(4):267–276.
    doi: 10.1038/sj.gt.3303072pubmed: 18033308google scholar: lookup
  30. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.. Cancer Gene Therapy 2012;19(12):852–861.
    doi: 10.1038/cgt.2012.72pubmed: 23059870google scholar: lookup
  31. Finocchiaro LME, Fondello C, Gil-Cardeza ML. Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.. Submitted .
    pmc: PMC4492668pubmed: 25762364
  32. Ehrhart N. Soft-tissue sarcomas in dogs: a review.. Journal of the American Animal Hospital Association 2005;41(4):241–246.
    doi: 10.5326/0410241pubmed: 15995161google scholar: lookup
  33. Thamm DH, Kurzman ID, Macewen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.. Cancer Immunology, Immunotherapy 2003;52(8):473–480.
    doi: 10.1007/s00262-003-0387-6pmc: PMC11032875pubmed: 12768328google scholar: lookup
  34. Finocchiaro LME, Villaverde MS, Gil-Cardeza ML, Riveros MD, Glikin GC. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas.. Research in Veterinary Science 2011;91(2):230–234.
    doi: 10.1016/j.rvsc.2010.12.012pubmed: 21300385google scholar: lookup
  35. Mayer MN, Grier CKP. Palliative radiation therapy for canine osteosarcoma.. Canadian Veterinary Journal 2006;47(7):707–709.
    pmc: PMC1482437pubmed: 16898117
  36. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases.. Human Gene Therapy 2005;16(8):937–946.
    doi: 10.1089/hum.2005.16.937pubmed: 16076252google scholar: lookup
  37. Finocchiaro LME, Spector A, Rossi UA. The potential of suicide plus immune gene therapy for treating osteosarcoma: the experience on canine veterinary patients.. 2012. pp. 107–122.
  38. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack J, Duke RC. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer.. Molecular Therapy 2012;20(12):2234–2243.
    doi: 10.1038/mt.2012.149pmc: PMC3519983pubmed: 22850679google scholar: lookup
  39. Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review.. Hematological Oncology 2013;31(1):1–9.
    doi: 10.1002/hon.2017pubmed: 22674797google scholar: lookup
  40. Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma.. Veterinary and Comparative Oncology 2007;5(4):219–231.
    doi: 10.1111/j.1476-5829.2007.00128.xpubmed: 19754780google scholar: lookup
  41. Lawman M, Eidizadeh S, Selmon C, Kane C, Xigacos L, Kaufman L, Shaw N, Lawman P. Anti-tumor response induced by autologous cancer vaccine in canine lymphoma.. Cancer Therapy 2008;6(2):827–840.
  42. Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.. Molecular Therapy 2010;18(8):1559–1567.
    doi: 10.1038/mt.2010.104pmc: PMC2927056pubmed: 20531395google scholar: lookup
  43. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma.. Human Gene Therapy 2013;24(8):728–738.
    doi: 10.1089/hum.2013.112pmc: PMC3746211pubmed: 23902422google scholar: lookup
  44. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma.. PLoS ONE 2011;6(8).
    doi: 10.1371/journal.pone.0024167pmc: PMC3164165pubmed: 21904611google scholar: lookup
  45. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs.. Cancer Gene Therapy 2010;17(7):457–464.
    doi: 10.1038/cgt.2010.6pmc: PMC3148143pubmed: 20150931google scholar: lookup
  46. Pluhar GE, Grogan PT, Seiler C, Goulart M, SantaCruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.. Vaccine 2010;28(19):3371–3378.
    doi: 10.1016/j.vaccine.2010.02.082pmc: PMC2854671pubmed: 20197146google scholar: lookup
  47. Cemazar M, Sersa G, Pavlin D, Tozon N. Intramuscular IL-12 electrogene therapy for treatment of spontaneous canine tumors.. 2011. pp. 299–320.
  48. Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors.. Radiology and Oncology 2011;45(1):31–39.
    doi: 10.2478/v10019-010-0041-9pmc: PMC3423723pubmed: 22933932google scholar: lookup
  49. Nande R, Di Benedetto A, Aimola P, de Carlo F, Carper M, Claudio CD, Denvir J, Valluri J, Duncan GC, Claudio PP. Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer.. PLoS ONE 2012;7(5).
    doi: 10.1371/journal.pone.0037743pmc: PMC3364269pubmed: 22666387google scholar: lookup
  50. Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Therapy 2003;10(26):2126–2132.
    doi: 10.1038/sj.gt.3302124pubmed: 14625567google scholar: lookup
  51. Siddiqui F, Li CY, LaRue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL, Thrall DE, Dewhirst MW, Hauck ML. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas.. Molecular Cancer Therapeutics 2007;6(1):380–391.
    doi: 10.1158/1535-7163.MCT-06-0342pubmed: 17237297google scholar: lookup
  52. Jahnke A, Hirschberger J, Fischer C, Brill T, Köstlin R, Plank C, Küchenhoff H, Krieger S, Kamenica K, Schillinger U. Intra-tumoral gene delivery of feIL-2, feIFN-γ and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study.. Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine 2007;54(10):599–606.
    doi: 10.1111/j.1439-0442.2007.01002.xpubmed: 18045346google scholar: lookup
  53. Hüttinger C, Hirschberger J, Jahnke A, Köstlin R, Brill T, Plank C, Küchenhoff H, Krieger S, Schillinger U. Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial.. Journal of Gene Medicine 2008;10(6):655–667.
    doi: 10.1002/jgm.1185pubmed: 18338834google scholar: lookup
  54. Phillips JC, Lembcke LM. Equine melanocytic tumors.. Veterinary Clinics of North America—Equine Practice 2013;29(3):673–687.
    doi: 10.1016/j.cveq.2013.08.008pubmed: 24267683google scholar: lookup
  55. Finocchiaro LME, Riveros MD, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse.. Veterinary Record 2009;164(9):278–279.
    doi: 10.1136/vr.164.9.278pubmed: 19252217google scholar: lookup
  56. Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, Moelling K. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses.. Journal of Molecular Medicine 2001;78(12):692–702.
    doi: 10.1007/s001090000165pubmed: 11434722google scholar: lookup
  57. Müller J, Feige K, Wunderlin P, Hödl A, Meli ML, Seltenhammer M, Grest P, Nicolson L, Schelling C, Heinzerling LM. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses.. Journal of Immunotherapy 2011;34(1):58–64.
    doi: 10.1097/CJI.0b013e3181fe1997pubmed: 21150713google scholar: lookup
  58. Müller JMV, Wissemann J, Meli ML, Dasen G, Lutz H, Heinzerling L, Feige K. In vivo induction of interferon gamma expression in grey horses with metastatic melanoma resulting from direct injection of plasmid DNA coding for equine interleukin 12.. Schweizer Archiv fur Tierheilkunde 2011;153(11):509–513.
    doi: 10.1024/0036-7281/a000262pubmed: 22045456google scholar: lookup
  59. Laborda E, Puig-Saus C, Rodriguez-García A, Moreno R, Cascalló M, Pastor J, Alemany R. A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.. Molecular Therapy 2014;22(5):986–998.
    doi: 10.1038/mt.2014.7pmc: PMC4015225pubmed: 24448161google scholar: lookup
  60. Kamstock D, Guth A, Elmslie R. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma.. Cancer Gene Therapy 2006;13(3):306–317.
    doi: 10.1038/sj.cgt.7700895pubmed: 16138118google scholar: lookup
  61. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.. Journal of Veterinary Internal Medicine 2007;21(1):113–120.
    doi: 10.1892/0891-6640(2007)21[113:EOANTV]2.0.CO;2pubmed: 17338158google scholar: lookup
  62. Paoloni MC, Khanna C. Comparative oncology today.. Veterinary Clinics of North America: Small Animal Practice 2007;37(6):1023–1032.
    doi: 10.1016/j.cvsm.2007.08.003pmc: PMC2174910pubmed: 17950880google scholar: lookup
  63. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer.. Trends in Molecular Medicine 2011;17(7):380–388.
    doi: 10.1016/j.molmed.2011.02.004pmc: PMC3130881pubmed: 21439907google scholar: lookup
  64. Ranieri G, Gadaleta CD, Patruno R. A model of study for human cancer: spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.. Critical Reviews in Oncology/Hematology 2013;88(1):187–197.
    doi: 10.1016/j.critrevonc.2013.03.005pubmed: 23561333google scholar: lookup
  65. Porrello A, Cardelli P, Spugnini EP. Pet models in cancer research: general principles.. Journal of Experimental and Clinical Cancer Research 2004;23(2):181–193.
    pubmed: 15354401
  66. Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients.. Clinical Cancer Research 2009;15(18):5671–5677.
    doi: 10.1158/1078-0432.CCR-09-0719pmc: PMC2748812pubmed: 19737961google scholar: lookup

Citations

This article has been cited 17 times.
  1. Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. Bull Math Biol 2025 May 28;87(7):86.
    doi: 10.1007/s11538-025-01462-wpubmed: 40434675google scholar: lookup
  2. Glikin GC, Finocchiaro LME. Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024). Vet Sci 2025 Apr 3;12(4).
    doi: 10.3390/vetsci12040329pubmed: 40284831google scholar: lookup
  3. Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. bioRxiv 2025 Jan 8;.
    doi: 10.1101/2025.01.06.631283pubmed: 39829889google scholar: lookup
  4. Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Dehlawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Mol Cancer Ther 2024 Aug 1;23(8):1139-1143.
    doi: 10.1158/1535-7163.MCT-23-0652pubmed: 38657233google scholar: lookup
  5. Sakuma S, Okamoto M, Matsushita N, Ukawa M, Tomono T, Kawamoto K, Ikeda T, Sakuma S. Evaluation of a (D)-Octaarginine-linked polymer as a transfection tool for transient and stable transgene expression in human and murine cell lines. J Vet Med Sci 2022 Apr 13;84(4):484-493.
    doi: 10.1292/jvms.21-0647pubmed: 35135938google scholar: lookup
  6. Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother 2020 Dec;69(12):2465-2476.
    doi: 10.1007/s00262-020-02634-4pubmed: 32556443google scholar: lookup
  7. Almela RM, Ansón A. A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma. Vet Sci 2019 Feb 12;6(1).
    doi: 10.3390/vetsci6010015pubmed: 30759787google scholar: lookup
  8. Strauss BE, Silva GRO, de Luna Vieira I, Cerqueira OLD, Del Valle PR, Medrano RFV, Mendonça SA. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics (Sao Paulo) 2018 Sep 6;73(suppl 1):e479s.
    doi: 10.6061/clinics/2018/e479spubmed: 30208166google scholar: lookup
  9. Finocchiaro LME, Spector AIM, Agnetti L, Arbe MF, Glikin GC. Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma. Vet Sci 2018 Aug 3;5(3).
    doi: 10.3390/vetsci5030070pubmed: 30081470google scholar: lookup
  10. Barutello G, Rolih V, Arigoni M, Tarone L, Conti L, Quaglino E, Buracco P, Cavallo F, Riccardo F. Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. Int J Mol Sci 2018 Mar 10;19(3).
    doi: 10.3390/ijms19030799pubmed: 29534457google scholar: lookup
  11. Agnetti L, Fondello C, Villaverde MS, Glikin GC, Finocchiaro LME. Therapeutic potential of bleomycin plus suicide or interferon-β gene transfer combination for spontaneous feline and canine melanoma. Oncoscience 2017 Nov;4(11-12):199-214.
    doi: 10.18632/oncoscience.387pubmed: 29344558google scholar: lookup
  12. Zuleger CL, Kang C, Ranheim EA, Kurzman ID, Macklin MD, Newton MA, Wolchok JD, Vail DM, Eriksson E, Albertini MR. Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma. Vet Med Sci 2017 Aug;3(3):134-145.
    doi: 10.1002/vms3.65pubmed: 29067210google scholar: lookup
  13. Finocchiaro LME, Glikin GC. Recent clinical trials of cancer immunogene therapy in companion animals. World J Exp Med 2017 May 20;7(2):42-48.
    doi: 10.5493/wjem.v7.i2.42pubmed: 28589078google scholar: lookup
  14. Piras LA, Riccardo F, Iussich S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. Vet Comp Oncol 2017 Sep;15(3):996-1013.
    doi: 10.1111/vco.12239pubmed: 27146852google scholar: lookup
  15. Anderson KL, Modiano JF. Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Vet Sci 2015 Dec;2(4):363-387.
    doi: 10.3390/vetsci2040363pubmed: 27066495google scholar: lookup
  16. Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, Miklavcic D. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015 Oct;64(10):1315-27.
    doi: 10.1007/s00262-015-1724-2pubmed: 26067277google scholar: lookup
  17. Finocchiaro LM, Fondello C, Gil-Cardeza ML, Rossi ÚA, Villaverde MS, Riveros MD, Glikin GC. Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma. Hum Gene Ther 2015 Jun;26(6):367-76.
    doi: 10.1089/hum.2014.130pubmed: 25762364google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.